Compare NetFlix Inc (NFLX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetFlix Inc vs BIO-TECHNE Corp — how do they compare? NetFlix Inc trades at $75.07 (market cap $317.67B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: NetFlix Inc is far larger — about 28.3× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while NetFlix Inc pays none. Which is the better fit depends on your goals.
| NFLX | TECH | |
|---|---|---|
Market Cap | $317.67B | $11.24B |
Sector | Consumer Cyclical | Health |
52-Week High | $126.33 | $72.29 |
52-Week Low | $67.60 | $43.31 |
Enterprise Value | $322.85B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Netflix (NFLX) trades at $74.79, up 0.88% on the day, showing resilience amid recent volatility. The stock exhibits strong fundamentals with robust revenue growth, expanding net income margins, and consistent earnings beats. Technical analysis indicates a bullish trend with key support at $74 and resistance at $77. Recent news highlights focus on the company's advertising business expansion and content performance.
The outlook for NFLX remains positive driven by advertising revenue growth and global subscriber expansion. Key risks include intense streaming competition and market sentiment shifts. Analyst consensus is strongly bullish with a $90.45 price target, suggesting significant upside potential from current levels.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetFlix Inc
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
